Effects of Initial Antihypertensive Drug Class on Patient Persistence and Compliance in a Usual-care Setting in the United States

Overview

Journal J Clin Hypertens (Greenwich)

Specialty Cardiology & Vascular Diseases

Date 2007 Sep 6

PMID 17786070

Citations 19

Authors

Bimal V Patel

Rosemay A Remigio-Baker

Devi Mehta

Patrick Thiebaud

Feride Frech-Tamas

Ronald Preblick

Affiliations

Soon will be listed here.

Abstract

Antihypertensive treatment regimen persistence and compliance were measured using a retrospective cohort study of pharmacy claims data. Newly treated patients receiving monotherapy with angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), beta-blockers (BBs), or diuretics were followed for 1 year (N=242,882). A higher proportion of ARB patients (51.9%) were persistent in taking prescribed medication compared with those in the ACEI (48.0%), BB (40.3%), CCB (38.3%), and diuretic groups (29.9%). Compared with patients receiving diuretics, those receiving ARBs (hazard ratio [HR], 0.593; P<.0001), ACEIs (HR, 0.640; P<.0001), CCBs (HR, 0.859; P<.0001), and BBs (HR, 0.819; P<.0001) were all less likely to discontinue therapy. Compliance was similar in ACEI and ARB patients, but patients receiving ARBs and ACEIs had better compliance than those receiving BBs, CCBs, or diuretics. The lesser degree of compliance and persistence observed in patients receiving diuretics compared with other antihypertensive medications may have public health as well as cost implications.

Citing Articles

Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: A 15-year cohort study.

Wu H, Peng C, Chen P, Chiang C, Chang C, Huang J PLoS One. 2017; 12(5):e0177654.

PMID: 28505194 PMC: 5432180. DOI: 10.1371/journal.pone.0177654.

Persistence to antihypertensive drug classes: A cohort study using the Swedish Primary Care Cardiovascular Database (SPCCD).

Qvarnstrom M, Kahan T, Kieler H, Brandt L, Hasselstrom J, Bengtsson Bostrom K Medicine (Baltimore). 2016; 95(40):e4908.

PMID: 27749548 PMC: 5059050. DOI: 10.1097/MD.0000000000004908.

Persistence and compliance with newly initiated antihypertensive drug treatment in patients with chronic kidney disease.

Truong V, Moisan J, Kroger E, Langlois S, Gregoire J Patient Prefer Adherence. 2016; 10:1121-9.

PMID: 27382260 PMC: 4922779. DOI: 10.2147/PPA.S108757.

Achieving Adherence After First-Line Antihypertensive Treatment: Should Fixed-Dose Combinations Receive Priority?.

Deshmukh K, Qian J, Garza K, Wright B, Zeng P, Ganduglia Cazaban C J Clin Hypertens (Greenwich). 2016; 18(9):934-41.

PMID: 26917089 PMC: 8031934. DOI: 10.1111/jch.12799.

Persistence with Antihypertensive Medications in Uncomplicated Treatment-Naïve Patients: Effects of Initial Therapeutic Classes.

Ah Y, Lee J, Choi Y, Kim B, Choi K, Kong J J Korean Med Sci. 2015; 30(12):1800-6.

PMID: 26713055 PMC: 4689824. DOI: 10.3346/jkms.2015.30.12.1800.

References

Gregoire J, Moisan J, Guibert R, Ciampi A, Milot A, Gaudet M . Determinants of discontinuation of new courses of antihypertensive medications. J Clin Epidemiol. 2002; 55(7):728-35. DOI: 10.1016/s0895-4356(02)00400-6. View

Ong K, Cheung B, Man Y, Lau C, Lam K . Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2006; 49(1):69-75. DOI: 10.1161/01.HYP.0000252676.46043.18. View

. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288(23):2981-97. DOI: 10.1001/jama.288.23.2981. View

Fields L, Burt V, Cutler J, Hughes J, Roccella E, Sorlie P . The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004; 44(4):398-404. DOI: 10.1161/01.HYP.0000142248.54761.56. View

Cramer J . Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence. Am J Manag Care. 1999; 4(11):1563-8. View

Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo Jr J . The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289(19):2560-72. DOI: 10.1001/jama.289.19.2560. View

Bourgault C, Senecal M, Brisson M, Marentette M, Gregoire J . Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens. 2005; 19(8):607-13. DOI: 10.1038/sj.jhh.1001873. View

Marentette M, Gerth W, Billings D, Zarnke K . Antihypertensive persistence and drug class. Can J Cardiol. 2002; 18(6):649-56. View

Conlin P, Gerth W, Fox J, Roehm J, Boccuzzi S . Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther. 2002; 23(12):1999-2010. DOI: 10.1016/s0149-2918(01)80152-1. View

10.

Pablos-Mendez A, Barr R, Shea S . Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA. 1998; 279(3):222-5. DOI: 10.1001/jama.279.3.222. View

11.

Caro J, Speckman J . Existing treatment strategies: does noncompliance make a difference?. J Hypertens Suppl. 1998; 16(7):S31-4. View

12.

Christensen D, Williams B, GOLDBERG H, Martin D, ENGELBERG R, LoGerfo J . Comparison of prescription and medical records in reflecting patient antihypertensive drug therapy. Ann Pharmacother. 1994; 28(1):99-104. DOI: 10.1177/106002809402800119. View

13.

Black H, Graff A, Shute D, Stoltz R, Ruff D, Levine J . Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens. 1997; 11(8):483-9. DOI: 10.1038/sj.jhh.1000482. View

14.

Sokol M, McGuigan K, Verbrugge R, Epstein R . Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005; 43(6):521-30. DOI: 10.1097/01.mlr.0000163641.86870.af. View

15.

Rizzo J, Simons W . Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther. 1998; 19(6):1446-57; discussion 1424-5. DOI: 10.1016/s0149-2918(97)80018-5. View

16.

McCombs J, Nichol M, Newman C, Sclar D . The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care. 1994; 32(3):214-26. DOI: 10.1097/00005650-199403000-00003. View

17.

Corea L, Cardoni O, Fogari R, Innocenti P, Porcellati C, Provvidenza M . Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther. 1996; 60(3):341-6. DOI: 10.1016/S0009-9236(96)90061-2. View

18.

Hajjar I, Kotchen T . Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003; 290(2):199-206. DOI: 10.1001/jama.290.2.199. View

19.

Choo P, Rand C, Inui T, Lee M, Cain E, Canning C . Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care. 1999; 37(9):846-57. DOI: 10.1097/00005650-199909000-00002. View

20.

Gregoire J, Moisan J, Guibert R, Ciampi A, Milot A, Cote I . Tolerability of antihypertensive drugs in a community-based setting. Clin Ther. 2001; 23(5):715-26. DOI: 10.1016/s0149-2918(01)80021-7. View